225 related articles for article (PubMed ID: 37258040)
21. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
22. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
23. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
[TBL] [Abstract][Full Text] [Related]
24. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models.
Schoutrop E; Poiret T; El-Serafi I; Zhao Y; He R; Moter A; Henriksson J; Hassan M; Magalhaes I; Mattsson J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746513
[TBL] [Abstract][Full Text] [Related]
25. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
[TBL] [Abstract][Full Text] [Related]
26. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.
Sharma P; Marada VVVR; Cai Q; Kizerwetter M; He Y; Wolf SP; Schreiber K; Clausen H; Schreiber H; Kranz DM
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15148-15159. PubMed ID: 32541028
[TBL] [Abstract][Full Text] [Related]
27. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
28. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
29. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
[TBL] [Abstract][Full Text] [Related]
30. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
32. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting.
Lee EHJ; Murad JP; Christian L; Gibson J; Yamaguchi Y; Cullen C; Gumber D; Park AK; Young C; Monroy I; Yang J; Stern LA; Adkins LN; Dhapola G; Gittins B; Chang WC; Martinez C; Woo Y; Cristea M; Rodriguez-Rodriguez L; Ishihara J; Lee JK; Forman SJ; Wang LD; Priceman SJ
Nat Commun; 2023 Aug; 14(1):4737. PubMed ID: 37550294
[TBL] [Abstract][Full Text] [Related]
33. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
[TBL] [Abstract][Full Text] [Related]
34. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
Martín-Otal C; Lasarte-Cia A; Serrano D; Casares N; Conde E; Navarro F; Sánchez-Moreno I; Gorraiz M; Sarrión P; Calvo A; De Andrea CE; Echeveste J; Vilas A; Rodriguez-Madoz JR; San Miguel J; Prosper F; Hervas-Stubbs S; Lasarte JJ; Lozano T
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35918123
[TBL] [Abstract][Full Text] [Related]
35. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
Shabaneh TB; Stevens AR; Stull SM; Shimp KR; Seaton BW; Gad EA; Jaeger-Ruckstuhl CA; Simon S; Koehne AL; Price JP; Olson JM; Hoffstrom BG; Jellyman D; Riddell SR
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38325903
[TBL] [Abstract][Full Text] [Related]
36. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
37. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
38. Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency.
Duan Y; Chen J; Meng X; Liu L; Shang K; Wu X; Wang Y; Huang Z; Liu H; Huang Y; Zhou C; Gao X; Wang Y; Sun J
Mol Ther; 2023 Jan; 31(1):35-47. PubMed ID: 36045585
[TBL] [Abstract][Full Text] [Related]
39. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
40. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
